Efgartigimod alfa (3) – Vyvgart®

• Clinical trials
  • The ADHERE study is a multi-stage Phase II trial designed to investigate the safety and efficacy of efgartigimod alfa for the treatment of CIDP.
  • In the subsequent double-blind, randomised and controlled phase (Stage B), patients received efgartigimod alfa or placebo.

Adults with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) following prior treatment with corticosteroids or immunoglobulins

• For adults with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) following prior treatment with corticosteroids or immunoglobulins, the additional benefit is not proven.
• The additional benefit of efgartigimod alfa compared with the appropriate comparator therapy in adults with progressive or relapsing active CIDP following prior treatment with corticosteroids or immunoglobulins is not proven.
• Conclusion
  • Overall, the data presented are not sufficient to demonstrate additional benefit compared with the appropriate comparator therapy.
  • Additional benefit from efgartigimod alfa for the treatment of adults with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) is not proven following prior treatment with corticosteroids or immunoglobulins.

Courtesy translation only, please refer to the German original.